Table 1. Viral diseases treated with vaccines prepared using the WI-38 cell strain or its derivatives, year each vaccine was introduced, annual cases, pre-vaccine annual deaths, and cases and deaths averted or treated from each disease from year of introduction to 2015 (with 95% coverage).
| Disease | YearIntroduced | Vaccineannual cases(U.S., 1960) | Pre-vaccineannual deaths(U.S.) | Cases averted or treated with 95% coverage | Deaths averted with 95% coverage |
| Poliomyelitis | 1963 | 36,110 | 5,865 | 2,547,045 | 413,692 |
| Measles | 1969–70 | 530,217 | 440 | 34,137,129 | 28,329 |
| Mumps | 1967 | 162,344 | 39 | 10,792,317 | 2,593 |
| Rubella | 1969 | 47,745 | 17 | 3,073,981 | 1,095 |
| Varicella (chicken pox) | 1995–96 | 4,085,120 | 107 | 133,691,807 | 3,436 |
| Hepatitis A | 1996 | 117,333 | 137 | 3,674,988 | 4,291 |
| Rabies# | 1974 | 18,000 | - | 10,000,000 | - |
| Adenovirus* | 1964 | 11,138 | - | 375,619 | - |
| Total (U.S.) | 5,017,007 | 6,603 | 198,292,887 | 453,435 |
Estimates of cases and deaths were obtained from the following sources:
Roush SW, Murphy TV (2007) JAMA 298: 2155-2163.
Population estimates were obtained from the following sources:
# The majority of cases of rabies treated with the WI-38 based vaccine occurred after the disease appeared rather than as a preventative measure (http://www.rightdiagnosis.com/r/rabies/stats.htm). The value of the WI-38 based rabies vaccine was that it eliminated the painful side effects associated with the previous vaccine made in neuronal tissue.
* The adenovirus was developed in 1966 and first administered to military personnel in 1971. Estimates provided here assume .04% of the total U.S. population served in the armed forces annually; prevalence of adenovirus among military forces is 1.1% annually; and these calculations apply only for the years 1971–1999 and 2011–2016 when the WI-38 related adenovirus vaccine was administered.